CO7160093A2 - Anticuerpos anti-egfr y usos de los mismos - Google Patents
Anticuerpos anti-egfr y usos de los mismosInfo
- Publication number
- CO7160093A2 CO7160093A2 CO14283133A CO14283133A CO7160093A2 CO 7160093 A2 CO7160093 A2 CO 7160093A2 CO 14283133 A CO14283133 A CO 14283133A CO 14283133 A CO14283133 A CO 14283133A CO 7160093 A2 CO7160093 A2 CO 7160093A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- egfr
- bind
- certain embodiments
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona anticuerpos que se unen a EGFR y métodos de uso de los mismos. De acuerdo con ciertas realizaciones de la invención, los anticuerpos son anticuerpos completamente humanos que se unen a EGFR con una afinidad elevada. En ciertas realizaciones, los anticuerpos de la presente invención son capaces de inhibir el crecimiento de células tumorales que expresan niveles elevados de EGRF y/o inducir citotoxicidad mediada por células dependiente de anticuerpos (ADCC) de tales células. Los anticuerpos de la invención son útiles para el tratamiento de diferentes cánceres así como de otros trastornos relacionados con EGFR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663984P | 2012-06-25 | 2012-06-25 | |
US201361821000P | 2013-05-08 | 2013-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7160093A2 true CO7160093A2 (es) | 2015-01-15 |
Family
ID=48782632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14283133A CO7160093A2 (es) | 2012-06-25 | 2014-12-24 | Anticuerpos anti-egfr y usos de los mismos |
Country Status (24)
Country | Link |
---|---|
US (3) | US9132192B2 (es) |
EP (1) | EP2864357B1 (es) |
JP (1) | JP6486268B2 (es) |
KR (1) | KR20150023387A (es) |
CN (1) | CN104411722B (es) |
AR (1) | AR091545A1 (es) |
AU (2) | AU2013280610B2 (es) |
BR (1) | BR112014029099A2 (es) |
CA (1) | CA2876697C (es) |
CL (1) | CL2014003465A1 (es) |
CO (1) | CO7160093A2 (es) |
EA (1) | EA030421B1 (es) |
ES (1) | ES2816645T3 (es) |
HK (1) | HK1206040A1 (es) |
IL (1) | IL235392B (es) |
MX (1) | MX356329B (es) |
MY (2) | MY181086A (es) |
NZ (1) | NZ701633A (es) |
PH (1) | PH12014502437B1 (es) |
SG (3) | SG11201407163XA (es) |
TW (2) | TWI641619B (es) |
UY (1) | UY34876A (es) |
WO (1) | WO2014004427A2 (es) |
ZA (1) | ZA201407927B (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9273143B2 (en) * | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
US8791244B2 (en) | 2011-09-30 | 2014-07-29 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
EP2970491A4 (en) * | 2013-03-15 | 2016-11-23 | Alper Biotech Llc | MONOCLONAL ANTIBODIES AGAINST EGFR AND USES THEREOF |
EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
US20170121399A1 (en) | 2014-05-16 | 2017-05-04 | Ablynx N.V. | Improved immunoglobulin variable domains |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CN105017424B (zh) * | 2015-08-31 | 2021-02-09 | 北京泱深生物信息技术有限公司 | 一种egfr抗体可变区及其应用 |
CN108602888B (zh) | 2015-10-23 | 2022-10-04 | 美勒斯公司 | 抑制癌症生长的结合分子 |
JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Egfr及び/またはerbb3遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
CN110914293A (zh) | 2017-07-06 | 2020-03-24 | 里珍纳龙药品有限公司 | 用于制备糖蛋白的细胞培养工艺 |
BR112020002695A2 (pt) | 2017-08-09 | 2020-08-25 | Merus N.V. | anticorpos que se ligam à egfr e cmet |
WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的***和方法 |
SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
CN111771000A (zh) | 2018-02-28 | 2020-10-13 | 瑞泽恩制药公司 | 用于鉴定病毒污染物的***和方法 |
WO2019175131A1 (en) * | 2018-03-14 | 2019-09-19 | F. Hoffmann-La Roche Ag | Method for affinity maturation of antibodies |
WO2019182901A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
CN108680746A (zh) * | 2018-06-05 | 2018-10-19 | 中国科学院合肥物质科学研究院 | 一种控制肺癌细胞活力的分子靶标及其应用 |
SG11202011970TA (en) | 2018-08-27 | 2020-12-30 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
EP3775926A1 (en) | 2018-08-30 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
CN113661177B (zh) * | 2019-03-22 | 2024-04-16 | 里珍纳龙药品有限公司 | EGFR x CD28多特异性抗体 |
CN113785203A (zh) | 2019-05-13 | 2021-12-10 | 里珍纳龙药品有限公司 | 改进的竞争性配体结合测定 |
CN113993544A (zh) * | 2019-07-24 | 2022-01-28 | 神州细胞工程有限公司 | 用于治疗egfr高表达的癌症的多变剂量方法 |
WO2021061790A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
CN115398236B (zh) | 2020-01-21 | 2024-06-11 | 瑞泽恩制药公司 | 用于糖基化的蛋白质的电泳的去糖基化方法 |
HRP20231031T1 (hr) | 2020-02-26 | 2023-12-22 | Vir Biotechnology, Inc. | Protutijela protiv sars-cov-2 |
WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
CA3191141A1 (en) | 2020-11-25 | 2022-06-02 | Hunter Chen | Sustained release formulations using non-aqueous membrane emulsification |
MX2023007225A (es) | 2020-12-17 | 2023-06-27 | Regeneron Pharma | Fabricacion de microgeles encapsuladores de proteina. |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
JP2024519407A (ja) | 2021-03-26 | 2024-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 混合プロトコルを作成するための方法およびシステム |
WO2022240757A1 (en) | 2021-05-10 | 2022-11-17 | Entrada Therapeutics, Inc. | Antigen-binding and antigen degradation constructs |
MX2023014246A (es) | 2021-06-01 | 2024-01-17 | Regeneron Pharma | Ensayos y reactivos de microchips de electroforesis capilar. |
US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
IL311248A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | PH meter calibration and repair |
IL311245A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | Systems and methods for pH modeling and control |
KR20240097864A (ko) | 2021-10-26 | 2024-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법 |
CN116333119B (zh) * | 2021-12-16 | 2024-02-23 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
WO2024015418A1 (en) | 2022-07-13 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Mild acid immunoassays for detection of analytes |
WO2024076926A1 (en) | 2022-10-03 | 2024-04-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies |
WO2024097660A2 (en) * | 2022-11-01 | 2024-05-10 | Providence Health & Services - Oregon | Monoclonal antibodies specific for fas ligand and uses thereof |
WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
PL181342B1 (pl) | 1994-03-17 | 2001-07-31 | Merck Patent Gmbh | Jednolancuchowe anty-EGFR Fv i przeciwciala anty-EGFR, czasteczka DNA, sposoby wytwarzania jednolancuchowego przeciwciala anty-EGFR i przeciwciala anty-EGFR oraz kompozycja farmaceutyczna PL PL PL PL PL PL PL |
US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
WO2002081649A2 (en) * | 2001-04-06 | 2002-10-17 | The Trustees Of The University Of Pennsylvania | ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF |
KR20090125840A (ko) | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체 |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
WO2003012072A2 (en) * | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
ES2376165T3 (es) * | 2002-07-15 | 2012-03-09 | F. Hoffmann-La Roche Ag | Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4. |
US8323987B2 (en) | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
CA2624781A1 (en) * | 2005-10-11 | 2007-04-19 | Ablynx N.V. | Nanobodies tm and polypeptides against egfr and igf-ir |
ATE461220T1 (de) * | 2005-11-12 | 2010-04-15 | Lilly Co Eli | Anti-egfr-antikörper |
US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
TWI527593B (zh) * | 2008-03-18 | 2016-04-01 | 建南德克公司 | 抗her2抗體-藥物結合物及化療劑之組合及使用方法 |
TWI496582B (zh) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
CN102356092B (zh) * | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
WO2010115553A1 (en) * | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-2/anti-c-met antibodies |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
WO2011156617A2 (en) * | 2010-06-09 | 2011-12-15 | Aveo Pharmaceuticals, Inc. | Anti-egfr antibodies |
-
2013
- 2013-06-20 TW TW102121841A patent/TWI641619B/zh not_active IP Right Cessation
- 2013-06-20 TW TW107129255A patent/TW201843172A/zh unknown
- 2013-06-25 EA EA201590085A patent/EA030421B1/ru not_active IP Right Cessation
- 2013-06-25 NZ NZ701633A patent/NZ701633A/en not_active IP Right Cessation
- 2013-06-25 KR KR20147035064A patent/KR20150023387A/ko not_active Application Discontinuation
- 2013-06-25 BR BR112014029099A patent/BR112014029099A2/pt not_active Application Discontinuation
- 2013-06-25 ES ES13735519T patent/ES2816645T3/es active Active
- 2013-06-25 CN CN201380033859.6A patent/CN104411722B/zh not_active Expired - Fee Related
- 2013-06-25 MY MYPI2017704291A patent/MY181086A/en unknown
- 2013-06-25 MY MYPI2014003097A patent/MY164604A/en unknown
- 2013-06-25 SG SG11201407163XA patent/SG11201407163XA/en unknown
- 2013-06-25 UY UY34876A patent/UY34876A/es unknown
- 2013-06-25 SG SG10201804151QA patent/SG10201804151QA/en unknown
- 2013-06-25 US US13/925,923 patent/US9132192B2/en active Active
- 2013-06-25 AU AU2013280610A patent/AU2013280610B2/en active Active
- 2013-06-25 JP JP2015518639A patent/JP6486268B2/ja active Active
- 2013-06-25 AR ARP130102231 patent/AR091545A1/es unknown
- 2013-06-25 MX MX2014014361A patent/MX356329B/es active IP Right Grant
- 2013-06-25 WO PCT/US2013/047476 patent/WO2014004427A2/en active Application Filing
- 2013-06-25 EP EP13735519.4A patent/EP2864357B1/en active Active
- 2013-06-25 CA CA2876697A patent/CA2876697C/en active Active
- 2013-06-25 SG SG10201610590UA patent/SG10201610590UA/en unknown
-
2014
- 2014-10-29 IL IL235392A patent/IL235392B/en active IP Right Grant
- 2014-10-30 ZA ZA2014/07927A patent/ZA201407927B/en unknown
- 2014-10-30 PH PH12014502437A patent/PH12014502437B1/en unknown
- 2014-12-19 CL CL2014003465A patent/CL2014003465A1/es unknown
- 2014-12-24 CO CO14283133A patent/CO7160093A2/es unknown
-
2015
- 2015-07-13 HK HK15106655.6A patent/HK1206040A1/xx unknown
- 2015-08-06 US US14/820,324 patent/US9789184B2/en active Active
-
2017
- 2017-09-11 US US15/700,665 patent/US20180036405A1/en not_active Abandoned
-
2018
- 2018-07-05 AU AU2018204895A patent/AU2018204895A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7160093A2 (es) | Anticuerpos anti-egfr y usos de los mismos | |
ECSP18011248A (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
AR088171A1 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
DOP2015000110A (es) | Anticuerpos anti-ceacam5 y usos de estos | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
UY35682A (es) | Anticuerpos anti-activina a y usos de los mismos | |
ECSP15043772A (es) | Heterociclos tricíclicos como inhibidores de la proteína bet | |
NI201500131A (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
NI201500094A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos. | |
CR20190140A (es) | Anticuerpos anti-cd27 | |
CR20160542A (es) | 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET | |
AR091837A1 (es) | Compuestos para inmunoterapia dirigida | |
AR091220A1 (es) | Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf | |
BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
EA201400625A1 (ru) | Антитела против pd-l1 и их применение | |
GT201300260A (es) | Composición que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinocetan (folfiri) | |
PE20160190A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados | |
BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. |